Q4FY21 Result Update - Indoco Remedies - ICICI Direct

Q4FY21 revenues grew 12.2% YoY to Rs. 305 crore. Export formulations grew 65.6% YoY to Rs. 132 crore driven by strong growth in regulated and emerging markets. Domestic formulations de-grew 13.0% YoY to Rs. 139 crore due to continued impact on anti-infective and respiratory segment. API segment remained subdued at Rs. 20 crore, down 1.5% YoY. EBITDA margins expanded 569 bps YoY to 17.9% on account of lower staff, travel & promotional spend partly offset by decline in gross margin performance. Subsequent EBITDA grew 64.4% YoY to Rs. 55 crore. PAT for the quarter came in at Rs. 25 crore (~4.7x YoY) vs. Rs. 5.4 crore in Q4FY20.

For details, click on the link below: Link to the report

Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.336.75 as compared to the previous close of Rs. 358.45. The total number of shares traded during the day was 51215 in over 2424 trades.

The stock hit an intraday high of Rs. 368.7 and intraday low of 333.6. The net turnover during the day was Rs. 17929347.

Source : Equity Bulls

Keywords